PeptideStack
5.2kquestions
20kanswers
220users

Is lipase worth drawing at baseline before starting mazdutide?

Asked 28 Apr 2025Modified 12 months agoViewed 34k times
30

Stated plainly: lipase · mazdutide.

I am trying to build something sustainable rather than something thorough that I will abandon.

I have already decided the broad direction; this is about the specifics.

What would you do, and what would make you change course?

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

284 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
a1c
a1c

Glycated haemoglobin as a ninety-day glycaemic average: what a change of half a point means, why it lags, and the conditions under which it…

108 questions
shareeditfollowflag
VR
askedv_ramaswamy40k3828 Apr 2025
4Two of us worked through this independently and arrived here, so it is at least reproducible. – vialroom 9 months ago
3Worth adding that the method section is where the answer usually is. – tabular_nums 7 months ago
add a comment

2 Answers

Accepted answer first, then by votes
33

Accepted answer

The hazard ratio is the relative effect. What changes decisions is the absolute effect, and converting between them requires the event rate in the control arm, which is usually in the same table and rarely in the abstract.

The early fall in estimated glomerular filtration rate on treatment is haemodynamic rather than structural. Reduced intraglomerular pressure lowers the filtration rate acutely and preserves the glomerulus chronically — the same pattern seen with renin-angiotensin blockade and with SGLT2 inhibition. A dip of a few millilitres per minute in the first weeks, followed by a shallower long-term slope, is the desired trajectory, not a warning sign.

Headline results, principal programmes

TrialAgentnDurationPrimary result
STEP 1Semaglutide 2.4 mg1,96168 wk−14.9 % vs −2.4 % weight
STEP 2Semaglutide 2.4 mg, T2DM1,21068 wk−9.6 % vs −3.4 % weight
SURMOUNT-1Tirzepatide 5/10/15 mg2,53972 wk−15 / −19 / −21 % weight
SURMOUNT-4Tirzepatide, withdrawal67088 wkContinued loss vs substantial regain
SELECTSemaglutide 2.4 mg17,604~40 moMACE HR 0.80 (0.72–0.90)
FLOWSemaglutide 1.0 mg, CKD3,533~3.4 yrRenal composite reduced; stopped early
SURMOUNT-OSATirzepatide, OSA46952 wkAHI reduced with and without PAP

Specifically, the rodent thyroid C-cell findings that generated the labelled warning appear to be species-specific: rodent C-cells express GLP-1 receptors at high density, human C-cells at very low density, and human calcitonin data across large trial populations has not reproduced the signal. A family history of medullary thyroid carcinoma or MEN2 is nonetheless a genuine contraindication rather than a theoretical one.

FLOW tested a composite renal endpoint — kidney failure, sustained 50 per cent eGFR decline, or renal or cardiovascular death — in type 2 diabetes with chronic kidney disease, and was stopped early for efficacy[1].

I would resist reading a subgroup finding as a result. Subgroups in these trials were not powered, and a striking subgroup in a large trial is the expected consequence of multiplicity.

If the trend across three draws is flat, the difference between draws one and two was noise. Most of what people react to is noise.

shareimprove this answerflag
LQ
answered · acceptedlipid_panel_q44k1385 Jul 2025
8I would add a sentence about sterility here, since it is the thing people skip. – plate_count_9k 5 months ago
7The placebo-arm figure is the part everyone omits. – Dr_Otto_Lindqvist 4 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
11

This is a question about what the trial was designed to answer, and the honest response is that it was not designed to answer this.

HbA1c is a weighted average, not a flat one: roughly half the signal comes from the most recent month. That is why a value drawn six weeks after a change already reflects most of the effect, and why a value drawn during rapid haematological turnover reflects something other than glycaemia.

The relevant detail is that a fasting lipid panel drawn during rapid weight loss reads oddly for a mechanical reason: mobilised adipose tissue delivers free fatty acids to the liver, and hepatic triglyceride export rises. Triglycerides can transiently increase while the person is doing exactly the right thing. Draw the panel when weight has been stable for a few weeks if you want an interpretable number.

The caveat is the population. Trial participants were screened, monitored and supported; the effect size in an unmonitored setting is not the trial effect size, and it is not obvious in which direction the difference runs.

Convert everything to an absolute effect before you compare two interventions. Relative effects are not comparable across different baseline risks.

shareimprove this answerflag
HP
answeredh_pergande86k25816 Jul 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.